PHARMACIST INTERVENTION In tertiary care environments, patients frequently present with advanced stages of disease and are managed using complex, multi-drug regimens. Such circumstances heighten the intricacy of clinical decision-making and increase the likelihood of medication-related errors. Mistakes involving inaccurate dosage calculations or inappropriate prescribing and administration can precipitate adverse drug events (ADEs), prolong hospital stays, and contribute to rising healthcare expenditures.[43]. Medication safety plays a vital role in ensuring quality patient care, yet mistakes involving pharmaceuticals remain a common challenge across healthcare systems worldwide. The World Health Organization (WHO) explains that a medication error refers to any avoidable incident that could result in the wrong use of a drug or cause harm to a patient while the medicine is being handled by a healthcare provider, the patient, or even a consumer. Such errors may arise at different stages of the medication process, including when drugs are prescribed, written down, prepared and dispensed, given to the patient, or monitored afterward [44]. It is recognized as one of the most vulnerable points. Medication errors, particularly prescribing errors, are recognized as a major source of harm in hospitalized patients, and such harm is formally categorized as preventable adverse drug events (pADEs) [45]. The prevalence of prescribing errors reported across studies shows substantial variability, ranging from 2% to 94%, which largely reflects differences in the structure and rigor of medicines management systems as well as the methodologies employed to detect and classify such errors [45]. Research indicates that a substantial proportion of drug-related problems, estimated to range from 50% to 80%, are preventable, highlighting the importance of identifying and addressing these issues [46]. The pharmacist has become an integral member of the multidisciplinary team providing clinical patient care in various healthcare settings [47]. Their presence in high-street, community-based premises allows convenient public access to health advice without appointment [48]. Clinical pharmacists play a key role in preventing and resolving such problems by recommending appropriate interventions. With reported acceptance rates varying between 41% and 96% [49]. Active involvement of clinical pharmacists in patient care rounds plays a pivotal role in enhancing medication safety. During these rounds, pharmacists undertake comprehensive medication reconciliation, ensuring that prescribed therapies are consistent with patients’ current treatment regimens and clinical needs [43]. They hold a central role in overseeing the complete cycle of medication use and are also trained to identify inconsistencies in prescriptions, work closely with physicians to correct mistakes, provide patients with clear guidance about their treatments, and support clinical decision-making processes [44]. In addition to this direct oversight, pharmacists contribute to the continuous professional development of healthcare staff by providing lifelong education on pharmacotherapy and safe prescribing practices. Evidence from clinical practice demonstrates that such integrated participation not only minimizes prescribing errors but also strengthens overall medication management strategies, thereby improving patient outcomes and fostering a culture of safety within healthcare institutions [43]. Through these responsibilities, pharmacists contribute significantly to reducing adverse drug events that often lead to hospital admissions. Their involvement not only helps in lowering the overall burden on healthcare systems by cutting costs but also enhances the quality of care and leads to better health outcomes for patients [44]. A pharmacist intervention (PI) refers to “any activity undertaken by the pharmacist which benefits the patient” such as prescribing errors to avoid negative outcomes and improve therapy effectiveness [45]. There are three principal approaches for evaluating the significance of individual pharmacist interventions (PI) and they are : It involves assessing the actual consequences of drug-related problems (DRPs), such as the severity of harm observed in the patient. It considers the outcomes following the implementation of a PI and subsequent patient follow-up, thereby focusing on measurable clinical results. It estimates the potential impact of an intervention, emphasizing situations where adverse outcomes could plausibly occur. It has 2 subtypes: 3A— prediction of the potential consequences of DRPs in the absence of a PI; and Approach 3B—prediction of the potential consequences of an implemented PI. In this context, the term actual denotes events that have already manifested in the patient, whereas potential refers to conditions that may arise if preventive measures are not undertaken [49]. There are 3 categories of Pharmacist Interventions and they are : CATEGORY PHARMACIST INTERVENTIONS SPECIFIC RESPONSES Adjustment of drug quantity • Dose modification: immediate adjustment of the amount administered. • Dosing changes: alteration in frequency or duration of therapy. • Schedule modification: redistribution of doses across the day. • Change dose • Change dosage strength • Change duration of treatment • Change schedule Modification of pharmacological strategy • Drug substitution: replacement with an alternative substance, formulation, or route of administration. • Drug addition: initiation of a new therapy not previously prescribed. • Drug withdrawal: discontinuation of one or more medications in use. • Start alternative therapy • Change dosage form • Change route • Start medication • Discontinue medication Patient education and adherence • Behavioural modification: strategies to reduce voluntary non-adherence. • Instruction on drug use: education to minimize errors and involuntary non-compliance. • Guidance on non-pharmacological measures: counselling on lifestyle, hygiene, and dietary practices supportive of therapeutic goals. • Enhance compliance • Provide patient education • Recommendation for therapeutic/disease state monitoring Table no. 5: Comparative overview of pharmacist interventions and specific responses [50] It is reasonable to infer that pharmacist interventions (PI) may benefit patients with cerebrovascular disease [47]. As experts in medicine and therapy management, pharmacists are well-positioned to play a crucial role in both primary and secondary prevention of stroke [48]. Primary prevention and early interventions have the potential to reduce the risk of stroke in individuals without symptoms, while secondary prevention interventions focus on reducing the risk of recurrence [51]. PIs have been shown to significantly reduce Drug-related problems (DRPs), shorten hospital stays, lower costs, and improve the effectiveness of drug therapy[48]. A DRP is defined as any event that interferes with desired health outcomes, leading to ineffective pharmacotherapy and potentially causing harm [52]. Drug-related problems (DRP) constitute a significant challenge in hospitalized patients, with considerable implications for patient safety and clinical outcomes. Drug-related problems are contributing to morbidity and mortality. The Norwegian system classification system (table no.6) identifies six main categories: Drug choice Dosing Adverse Drug Reaction (examples in table no. 6) Interaction Drug Use Alternative [52]. Types of Drug-Related Problems Drug without indication Drug duplication Sub-therapeutic Dose Overdose Adverse Drug Reactions Improper Drug Selection Failure to Receive Drugs Medication Errors Untreated Indication Here’s the information neatly organized into a table format: Atorvastatin Hepatotoxicity, Myopathy Aspirin + Dipyridamole, Cilostazol Headache, Palpitation, Tachycardia Warfarin Upper Gastrointestinal Bleeding Table no. 6: Examples of DRP’S Concise this to half page

Still reduce to half page